Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
If you want a Stock Review on PFE, SNY, HRTX, or AERI then come over to http://dailystocktracker.com/register and …
Shares of Sanofi SA (SNYNF,SNY) were losing around 2 percent in the morning trading in Paris after the French drug giant reported Thursday a decline in third quarter profit, while net sales were slightly higher amid negative currency …
All of the foregoing was an obvious breath of fresh air at Sanofi at the time, but it now looks as if the French board has had enough. Bernstein analyst Tim Anderson, the dean of the pharma stock investment community, summed up the …
Third-quarter and first nine months 2017 income statements also reflect the …
After declining in 2016, share price of French pharma giant Sanofi SNY has picked up in 2017. This Zacks Rank #2 (Buy) stock has risen 21.1% this year so far, outperforming the return of the Zacks classified Large-Cap Pharma industry of …
Sanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan Paris, France - June 15, 2017 - Sanofi (http://en.sanofi.com/index.aspx) announced today the launch of "Action 2017", a worldwide stock purchase plan …
Paris, France based Sanofi SNY is a global healthcare company possessing a diversified product portfolio. It has a presence in several therapeutic areas including cardiovascular diseases, diabetes, oncology, and central nervous …
Sanofi collaboration revenue and Bayer collaboration revenue all beat expectations. Sales of its lead retinal therapy Eylea rose 12% to $953 million, beating the FactSet consensus of $935 million. The stock has fallen 14% over the past three …